Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 154-93-8
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of carmustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as carmustine.[1] The manufacturer recommends that breastfeeding be discontinued during carmustine therapy and for 1 month after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Some evidence indicates that carmustine can increase serum prolactin.[2] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
References
- 1.
- Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013;39:207–11. [PubMed: 23199900]
- 2.
- Constine LS, Rubin P, Woolf PD, et al. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol. 1987;5:1841–51. [PubMed: 3681371]
Substance Identification
Substance Name
Carmustine
CAS Registry Number
154-93-8
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Bendamustine.[Drugs and Lactation Database (...]Review Bendamustine.. Drugs and Lactation Database (LactMed®). 2006
- Antitumor activity of new nitrosoureas on Yoshida sarcoma ascites cells implanted into the colon wall of rats.[J Cancer Res Clin Oncol. 1981]Antitumor activity of new nitrosoureas on Yoshida sarcoma ascites cells implanted into the colon wall of rats.Habs M, Reinbold H, Eisenbrand G, Bhide S, Goga-Ionescu S, Schmähl D. J Cancer Res Clin Oncol. 1981; 101(3):285-302.
- Review Dacarbazine.[Drugs and Lactation Database (...]Review Dacarbazine.. Drugs and Lactation Database (LactMed®). 2006
- Review Temozolamide.[Drugs and Lactation Database (...]Review Temozolamide.. Drugs and Lactation Database (LactMed®). 2006
- The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.[Health Technol Assess. 2007]The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K. Health Technol Assess. 2007 Nov; 11(45):iii-iv, ix-221.
- Carmustine - Drugs and Lactation Database (LactMed®)Carmustine - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...